diagnosed as "acute PJI" (2, 3) . The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Ethical committee approval was not needed because of the study design. Demographic findings and details of the management of PJI were obtained from the database of the hospital and the researchers' records of the patients. Microsoft Excel was used for statistical analysis. Results are given in numbers and percentages.
Twenty-two patients with the diagnosis of acute PJI, either early acute or delayed acute (4), were included: 13 (59%) women and nine (41%) men, with a median age of 68 years (39-87 years). Ten (45%) patients had PJI of the hip, while the remaining patients had PJI of the knee (n = 12, 55%). All patients (100%) presented with warm, swollen, and painful joints. None of them had wound discharge. Median laboratory values were as follows: white blood cell (WBC) count, 7800/µL (5800-15,660/ µL); C-reactive protein (CRP), 35 mg/L (5-93 mg/L); and erythrocyte sedimentation rate, 55 mm/h (30-107 mm/h). Five (24%) patients had diabetes mellitus, one (5%) had rheumatoid arthritis, and three (14%) had malignancy. All but one of the patients had previous interventions for the treatment of PJI: either debridement and retention (n = 2, 0.9%) or one-stage (n = 2, 0.9%) or two-stage exchange operations (n = 17, 77%). The causative agents of PJI are shown in Table 1 . Fifteen (68%) patients received empirical antibiotic therapy. Details of antibiotic therapies for the management of PJI were available for 19 patients ( Table  2 ). In five (23%) patients, rifampicin was added to therapy. Five patients (23%) needed changes in antibiotic therapy in follow-up: from ampicillin sulbactam + ciprofloxacin to teicoplanin + sulbactam cefoperazone (n = 4, 18%) and from teicoplanin + ciprofloxacin to antifungal therapy (n = 1, 5%) according to either clinical unresponsiveness or culture results. Other than one patient who needed multiple operations and suppressive antibiotic therapy, the other patients responded to therapy (96%). When those two who were under antifungal therapy and under suppressive therapy were excluded, the median duration of antibiotic treatment for two-stage operations was 6 weeks (4-8 weeks), while it could be prolonged up to 6 months for one-stage operations. The patient whose treatment was changed to antifungal therapy needed multiple debridement after a two-stage exchange operation. Previously he was under teicoplanin plus ciprofloxacin therapy because of a PJI caused by Enterococcus faecalis. That PJI was under control and the prosthesis was removed, but non-albicans Candida was cultured from tissue and synovial fluid samples of the patient in the second stage of the operation. Two more cultures of synovial fluid showed the same organism afterwards. Antifungal therapy was started with amphotericin B (4 weeks), followed by voriconazole (1 months), and later continued with fluconazole for up to 1 year in duration. He recovered without any sequelae.
In our study, the median WBC count was within normal limits and CRP levels were increased only by 6-to 7-fold, which was unhelpful for definitive diagnosis. Main findings for PJI diagnosis were based on some clinical findings like pain, warmth, swelling, and redness of the affected joint and in addition to these either purulence of synovial fluid or growth of the etiologic agent from tissue or synovial fluid culture. Delayed diagnosis can cause harmful effects to prostheses. Clinical findings guided our prompt diagnosis. The empirical therapies of PJI mainly included broad-spectrum antibiotics because of the possible nosocomial source of infection in patients who had multiple operation histories. As seen in our results, almost one-third of the patients had gram-negative etiology and the agent was unknown in many patients. Thus, the empirical treatment had gram-negative coverage as well. Teicoplanin was the most preferred antibiotic for gram-positive coverage, with a successful outcome. Still, one patient needed suppressive antibiotic therapy while another patient experienced fungal PJI after a long-term broad-spectrum treatment.
There are limitations of this study. It was a retrospective study and the relation between therapy duration and exact clinical and laboratory response was not closely monitored. Although we have records, the details of synovial fluid analysis and surgical interventions were not available for all subjects and this retrospective study cannot state the success of medical therapy alone. The details of surgical interventions were lacking for some patients. Synovial fluid analysis was done for all patients but the detailed results were not available for all patients.
In conclusion, although there are many advantages of teicoplanin use in PJI (good soft tissue and bone concentrations, administration once a day in outpatient parenteral therapy, tolerability, safety) and it is even 
